NEUROCRINE BIOSCIENCES INCNBIX

Market cap

$15.3B

P/E ratio

	2011/12	2012/12	2013/12	2014/12	2015/12	2016/12	2017/12	2018/12	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12
Cash and cash equivalents	50	64	45	31	74	83	255	147	115	190	344	271	259	241
Marketable securities, current	79	109	101	326	305	224	522	1,018	1,116	1,228	741	726	781	843
Total cash & short-term investments	129	173	146	357	379	307	777	1,166	1,232	1,418	1,085	997	1,040	1,084
Accounts receivable, net	-	-	-	-	-	-	31	56	127	157	186	350	-	479
Inventories	-	-	-	-	-	-	-	11	17	28	31	35	38	57
Total current assets	132	189	148	198	384	310	555	738	831	1,016	973	1,454	1,607	1,725
Property, plant and equipment, net	2	2	2	3	3	6	11	34	42	45	59	59	71	83
Marketable securities, non-current	-	0	-	37	82	43	247	216	300	227	561	299	688	740
Total non-current assets	6	7	6	45	91	55	263	255	475	719	1,100	915	1,644	1,994
Total assets	138	196	155	243	475	365	818	993	1,306	1,735	2,073	2,369	3,251	3,719
Accounts payable	1	1	0	0	3	5	-	-	-	-	-	-	-	-
Total current liabilities	47	16	12	16	26	30	54	88	565	187	246	538	655	508
Total non-current liabilities	31	26	23	19	25	20	391	424	104	422	453	123	365	621
Total liabilities	78	42	34	34	50	50	445	512	669	609	699	661	1,019	1,129
Common stock and paid-in capital	785	874	886	1,035	0	0	0	0	0	0	0	0	0	0
Retained earnings	-725	-720	-766	-826	-915	-1,056	-1,199	-1,178	-1,133	-725	-636	-407	-157	29
Stockholders' equity	60	154	120	209	424	315	372	481	637	1,126	1,374	1,708	2,232	2,590